Eton Pharmaceuticals, Inc. (ETON) income statement
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30517% above fair value
$61.99−1.66 (-2.61%)
Close on Nov 18, 2026Market cap $1.77BP/E 158.9Yield –
Eton Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 57.9%
- Operating margin
- 15.4%
- Net margin
- 12.0%
- Return on equity, FY2025
- -18.2%
Financial strength
- Current ratio
- 1.52
- Debt to equity
- 0.60
- Debt to assets
- 24.1%
- Cash to current liabilities
- 59.5%
Valuation
- P/E ratio
- 158.9
- Price to sales
- 16.78
- Price to book
- 38.04
- Dividend yield
- –
See a number that looks wrong?